Bliss GVS Pharma Limited

BLISSGVS.BO · Bombay Stock Exchange · INR

651,10INR

+31,00 (+5,00 %)Stand 9. Nov., 9:57

Vortag 620,10

Kennzahlen

Eröffnung
623,70
Vortag
620,10
Tagesspanne
605,25 – 651,10
52 Wochen
118,35 – 744,75
Volumen
4698
Ø Volumen
20.064
Börsenwert
69,69 Mrd. INR
KGV
–
Gewinn je Aktie (TTM)
–
Dividendenrendite
–
Beta
1,1
Nächste Zahlen
–

Finanzen

Gerade nicht verfügbar.

Bewertung

Gerade nicht verfügbar.

Analysten

Einstufungen

Gerade nicht verfügbar.

Kursziel

Gerade nicht verfügbar.

Quartalszahlen

Gerade nicht verfügbar.

Dividenden und Splits

Gerade nicht verfügbar.

Aktiensplits

Gerade nicht verfügbar.

Eigentümer

Institutionen

Gerade nicht verfügbar.

Insider-Geschäfte

Gerade nicht verfügbar.

Vergleichbare Unternehmen

Gerade nicht verfügbar.

Über das Unternehmen

Bliss GVS Pharma Limited, founded in 1984 and based in Mumbai, India, operates as a pharmaceutical enterprise focused on the development, production, and commercialization of a vast array of medicinal formulations and general healthcare items. Its comprehensive pharmaceutical offerings span numerous dosage forms, such as capsules, tablets, injections, oral suspensions, topical creams/gels/ointments, effervescent tablets, eye/ear drops, transdermal patches, and parenterals. In addition to prescription pharmaceuticals, the company manufactures a wide selection of over-the-counter (OTC) and personal care products, including balms, lotions, shampoos, soaps, nasal inhalers, and various sprays and solutions. Addressing a broad spectrum of medical conditions, Bliss GVS's therapeutic catalogue features anti-infectives (e.g., antibacterial, anti-malarial, anti-fungal), anti-inflammatory agents, analgesics, gastrointestinal treatments (such as anti-ulcer and anti-diarrheal medications), anti-diabetics, respiratory support products (like antitussives and nasal decongestants), and an extensive range of nutritional, dermatological, and general wellness supplements, including vitamins, body supplements, and specialized hygiene solutions. The company's products are also distributed internationally through its export operations.

CEO
Shibroor Narsimha Kamath
Mitarbeitende
1.033
Hauptsitz
Mumbai, MA, IN
Sektor
Healthcare
Branche
Drug Manufacturers - Specialty & Generic
Börsengang
11. Jan. 2002

Nachrichten

Gerade nicht verfügbar.

Kurse mindestens 15 Minuten verzögert. Daten: Financial Modeling Prep. Keine Anlageberatung.